000 01242 a2200337 4500
005 20250515091534.0
264 0 _c20080904
008 200809s 0 0 eng d
022 _a0344-5704
024 7 _a10.1007/s00280-007-0616-3
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMeany, Holly J
245 0 0 _aThe plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
_h[electronic resource]
260 _bCancer chemotherapy and pharmacology
_cAug 2008
300 _a387-92 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnimals
650 0 4 _aArea Under Curve
650 0 4 _aErlotinib Hydrochloride
650 0 4 _aInjections, Intravenous
650 0 4 _aMacaca mulatta
650 0 4 _aMale
650 0 4 _aMetabolic Clearance Rate
650 0 4 _aQuinazolines
_xadministration & dosage
700 1 _aFox, Elizabeth
700 1 _aMcCully, Cynthia
700 1 _aTucker, Chris
700 1 _aBalis, Frank M
773 0 _tCancer chemotherapy and pharmacology
_gvol. 62
_gno. 3
_gp. 387-92
856 4 0 _uhttps://doi.org/10.1007/s00280-007-0616-3
_zAvailable from publisher's website
999 _c17453408
_d17453408